Although it has been recently reported that PP2A inhibition is a frequent alteration in breast cancer related with poor outcome and therapy resistance, such studies have been carried out in cohorts including cases with different molecular subtypes [40,45,46]. The gene discussed is PTPA; the disease is breast cancer.